{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:41:31Z","timestamp":1790635291224,"version":"4.1.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"DOI":"10.1007\/s00417-024-06587-7","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T09:02:16Z","timestamp":1725094936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Quintessence of currently approved and upcoming treatments for dry eye disease"],"prefix":"10.1007","author":[{"given":"Sunanda","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayatri","family":"Sawale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Ghuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhana","family":"Sathaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,31]]},"reference":[{"key":"6587_CR1","unstructured":"Golden MI, Meyer JJ, Patel BC (2023) Dry eye syndrome. [Updated 2023 Apr 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470411\/"},{"issue":"Suppl 1","key":"6587_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/01.icu.0000512373.81749.b7","volume":"27","author":"MS Milner","year":"2017","unstructured":"Milner MS, Beckman KA, Luchs JI et al (2017) Dysfunctional tear syndrome: Dry Eye Disease and Associated Tear Film Disorders - new strategies for diagnosis and treatment. Curr Opin Ophthalmol 27(Suppl 1):3\u201347. https:\/\/doi.org\/10.1097\/01.icu.0000512373.81749.b7","journal-title":"Curr Opin Ophthalmol"},{"key":"6587_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo C-K, Liu Z, Nelson JD, Nichols JJ, Tsubota K et al (2017) TFOS DEWS II definition and classification report. Ocul Surf 15:276\u2013283. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.008","journal-title":"Ocul Surf"},{"issue":"3","key":"6587_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"Alves\u2008M Stapleton\u2008F","year":"2017","unstructured":"Stapleton\u2008F Alves\u2008M (2017) Bunya\u2008VY, Jalbert\u2008I, Lekhanont\u2008K, Malet\u2008F. \u2008TFOS DEWS II Epidemiology Report. Ocul Surf 15(3):334\u2013365. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.003","journal-title":"Ocul Surf"},{"issue":"5","key":"6587_CR5","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s40123-022-00540-9","volume":"11","author":"K Kaur","year":"2022","unstructured":"Kaur K, Gurnani B, Nayak S, Deori N, Kaur S, Jethani J, Singh D, Agarkar S, Hussaindeen JR, Sukhija J, Mishra D (2022) Digital Eye Strain- A Comprehensive Review. Ophthalmol Ther 11(5):1655\u20131680. https:\/\/doi.org\/10.1007\/s40123-022-00540-9","journal-title":"Ophthalmol Ther"},{"key":"6587_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jtos.2016.11.003","volume":"15","author":"J Ben\u00edtez-Del-Castillo","year":"2017","unstructured":"Ben\u00edtez-Del-Castillo J, Labetoulle M, Baudouin C, Rolando M, Akova YA, Aragona P, Geerling G, Merayo-Lloves J, Messmer EM, Boboridis K (2017) Visual acuity and quality of life in Dry Eye Disease: Proceedings of the OCEAN Group Meeting. Ocul Surf 15:169\u2013178. https:\/\/doi.org\/10.1016\/j.jtos.2016.11.003","journal-title":"Ocul Surf"},{"issue":"2","key":"6587_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40135-013-0009-1","volume":"1","author":"M Uchino","year":"2013","unstructured":"Uchino M, Schaumberg DA (2013) Dry Eye Disease: Impact on Quality of Life and Vision. Curr Ophthalmol Rep 1(2):51\u201357. https:\/\/doi.org\/10.1007\/s40135-013-0009-1","journal-title":"Curr Ophthalmol Rep"},{"issue":"1","key":"6587_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/2211-5056.369606","volume":"13","author":"A Nguyen","year":"2023","unstructured":"Nguyen A, Kolluru A, Beglarian T (2023) Dry Eye Disease: a review of anti-inflammatory therapies. Taiwan J Ophthalmol 13(1):3\u201312. https:\/\/doi.org\/10.4103\/2211-5056.369606","journal-title":"Taiwan J Ophthalmol"},{"key":"6587_CR9","doi-asserted-by":"publisher","first-page":"106206","DOI":"10.1016\/j.ejps.2022.106206","volume":"175","author":"HB Mohamed","year":"2022","unstructured":"Mohamed HB, Abd El-Hamid BN, Fathalla D, Fouad EA (2022) Current trends in Pharmaceutical Treatment of Dry Eye Disease: a review. Eur J Pharm Sci 175:106206. https:\/\/doi.org\/10.1016\/j.ejps.2022.106206","journal-title":"Eur J Pharm Sci"},{"key":"6587_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/OPTO.S350185","volume":"15","author":"DA Semp","year":"2023","unstructured":"Semp DA, Beeson D, Sheppard AL, Dutta D, Wolffsohn JS (2023) Artificial tears: a systematic review. Clin Optom (Auckl) 15:9\u201327. https:\/\/doi.org\/10.2147\/OPTO.S350185","journal-title":"Clin Optom (Auckl)"},{"issue":"3","key":"6587_CR11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Downie LE, Korb D et al (2017) TFOS DEWS II Management and Therapy Report. Ocul Surf 15(3):575\u2013628. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.006","journal-title":"Ocul Surf"},{"issue":"3","key":"6587_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.4155\/cli.14.135","volume":"5","author":"P Ames","year":"2015","unstructured":"Ames P, Galor A (2015) Cyclosporine Ophthalmic emulsions for the treatment of Dry Eye: a review of the clinical evidence. Clin Investig (Lond) 5(3):267\u2013285. https:\/\/doi.org\/10.4155\/cli.14.135","journal-title":"Clin Investig (Lond)"},{"key":"6587_CR13","unstructured":"RESTASIS\u00ae prescribing information (2017). https:\/\/media.allergan.com\/actavis\/actavis\/media\/allergan-pdf-documents\/product-prescribing\/Combined-Restasis-and-MultiDose-PI_8-3-17.pdf. Accessed on 23 December 2023"},{"key":"6587_CR14","unstructured":"VEVYE\u00ae Prescribing Information (2023). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217469s000lbl.pdf. Accessed on 23 December 2023"},{"key":"6587_CR15","unstructured":"Novaliq press release. https:\/\/www.novaliq.com\/press-releases\/2023\/06\/08\/novaliq-announces-fda-approval-of-vevye-cyclosporine-ophthalmic-solution-0-1-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease\/. Accessed on 23 December 2023"},{"key":"6587_CR16","unstructured":"CEQUA\u2122 Prescribing Information (2018). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210913s000lbl.pdf. Accessed on 23 December 2023"},{"key":"6587_CR17","doi-asserted-by":"publisher","first-page":"251584141987036","DOI":"10.1177\/2515841419870366","volume":"11","author":"SL Haber","year":"2019","unstructured":"Haber SL, Benson V, Buckway CJ, Gonzales JM, Romanet D, Scholes B, Lifitegrast (2019) A Novel Drug for patients with Dry Eye Disease. Ther Adv Ophthalmol 11:2515841419870366. https:\/\/doi.org\/10.1177\/2515841419870366","journal-title":"Ther Adv Ophthalmol"},{"key":"6587_CR18","unstructured":"XIIDRA\u00ae Prescribing Information (2020). https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/xiidra.pdf. Accessed on 23 December 2023"},{"issue":"1","key":"6587_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/jop.2016.0105","volume":"33","author":"SC Pflugfelder","year":"2017","unstructured":"Pflugfelder SC, Stern M, Zhang S, Shojaei A (2017) LFA-1\/ICAM-1 Interaction as a therapeutic target in Dry Eye Disease. J Ocul Pharmacol Ther 33(1):5\u201312. https:\/\/doi.org\/10.1089\/jop.2016.0105","journal-title":"J Ocul Pharmacol Ther"},{"issue":"7","key":"6587_CR20","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1089\/jop.2020.0014","volume":"36","author":"K Beckman","year":"2020","unstructured":"Beckman K, Katz J, Majmudar P, Rostov A (2020) Loteprednol Etabonate for the treatment of Dry Eye Disease. J Ocul Pharmacol Ther 36(7):497\u2013511. https:\/\/doi.org\/10.1089\/jop.2020.0014","journal-title":"J Ocul Pharmacol Ther"},{"key":"6587_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/OPTH.S323301","volume":"16","author":"N Venkateswaran","year":"2022","unstructured":"Venkateswaran N, Bian Y, Gupta PK (2022) Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic suspension 0.25% in the management of Dry Eye Disease. Clin Ophthalmol 16:349\u2013355. https:\/\/doi.org\/10.2147\/OPTH.S323301","journal-title":"Clin Ophthalmol"},{"key":"6587_CR22","unstructured":"EYSUVIS\u2122 Prescribing Information (2020). https:\/\/www.eysuvis-ecp.com\/pdf\/prescribing-information.pdf. Accessed on 23 December 2023"},{"key":"6587_CR23","unstructured":"Hutton D (2023) Dry eye paradise: FDA green-lights Miebo as first and only eye drop approved for the condition. Ophthalmol Times 48(6). Digital Edition. https:\/\/www.ophthalmologytimes.com\/view\/dry-eye-paradise-fda-green-lights-miebo-as-first-and-only-eye-drop-approved-for-the-condition. Accessed on 27 January 2023"},{"key":"6587_CR24","unstructured":"MIEBO\u2122 Prescribing Information (2023). https:\/\/pi.bausch.com\/globalassets\/pdf\/packageinserts\/pharma\/miebo-package-insert.pdf. Accessed on 23 December 2023"},{"issue":"14 Suppl","key":"6587_CR25","doi-asserted-by":"publisher","first-page":"S251","DOI":"10.37765\/ajmc.2023.89464","volume":"29","author":"JD Sheppard","year":"2023","unstructured":"Sheppard JD, Evans DG, Protzko EE (2023) A review of the first anti-evaporative prescription treatment for Dry Eye Disease: Perfluorohexyloctane Ophthalmic Solution. Am J Manag Care 29(14 Suppl):S251\u2013S259. https:\/\/doi.org\/10.37765\/ajmc.2023.89464","journal-title":"Am J Manag Care"},{"issue":"14","key":"6587_CR26","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s40265-022-01782-4","volume":"82","author":"JE Frampton","year":"2022","unstructured":"Frampton JE (2022) Varenicline Solution Nasal Spray: a review in Dry Eye Disease. Drugs 82(14):1481\u20131488. https:\/\/doi.org\/10.1007\/s40265-022-01782-4","journal-title":"Drugs"},{"key":"6587_CR27","unstructured":"TYRVAYA\u2122 Prescribing Information (2021). https:\/\/www.tyrvaya-pro.com\/files\/prescribing-information.pdf. Accessed on 23 December 2023"},{"key":"6587_CR28","unstructured":"Lumenis Press Release (2021). https:\/\/lumenis.com\/vision\/resource-hub\/lumenis-receives-fda-approval-for-its-ipl-device-to-manage-dry-eye-disease-and-launches-optilight\/. Accessed on 23 December 2023"},{"key":"6587_CR29","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.2147\/OPTH.S349596","volume":"16","author":"B Barbosa Ribeiro","year":"2022","unstructured":"Barbosa Ribeiro B, Marta A, Ponces Ramalh\u00e3o J, Marques JH, Barbosa I (2022) Pulsed light therapy in the management of Dry Eye Disease: current perspectives. Clin Ophthalmol 16:3883\u20133893. https:\/\/doi.org\/10.2147\/OPTH.S349596","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"6587_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/pho.2014.3819","volume":"33","author":"R Toyos","year":"2015","unstructured":"Toyos R, McGill W, Briscoe D (2015) Intense pulsed light treatment for Dry Eye Disease due to Meibomian Gland Dysfunction: a 3-year Retrospective Study. Photomed Laser Surg 33(1):41\u201346. https:\/\/doi.org\/10.1089\/pho.2014.3819","journal-title":"Photomed Laser Surg"},{"issue":"2","key":"6587_CR31","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3892\/etm.2020.8838","volume":"20","author":"S Liu","year":"2020","unstructured":"Liu S, Tang S, Dong H, Huang X (2020) Intense pulsed light for the treatment of Meibomian Gland Dysfunction: a systematic review and Meta-analysis. Exp Ther Med 20(2):1815\u20131821. https:\/\/doi.org\/10.3892\/etm.2020.8838","journal-title":"Exp Ther Med"},{"issue":"6","key":"6587_CR32","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1089\/pho.2017.4402","volume":"36","author":"B Rong","year":"2018","unstructured":"Rong B, Tang Y, Tu P et al (2018) Intense pulsed light Applied directly on eyelids combined with Meibomian Gland expression to treat Meibomian Gland Dysfunction. Photomed Laser Surg 36(6):326\u2013332. https:\/\/doi.org\/10.1089\/pho.2017.4402","journal-title":"Photomed Laser Surg"},{"key":"6587_CR33","unstructured":"Sight Sciences Press Release (2021). https:\/\/www.sightsciences.com\/us\/sight-sciences-receives-fda-510k-clearance-of-the-tearcare-system-for-treatment-of-meibomian-gland-dysfunction-mgd-the-leading-cause-of-dry-eye-disease\/. Accessed on 23 December 2023"},{"key":"6587_CR34","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2147\/OPTH.S160403","volume":"12","author":"DA Badawi","year":"2018","unstructured":"Badawi DA, Novel System (2018) TearCare\u00ae, for the treatment of the signs and symptoms of Dry Eye Disease. Clin Ophthalmol 12:683\u2013694. https:\/\/doi.org\/10.2147\/OPTH.S160403","journal-title":"Clin Ophthalmol"},{"key":"6587_CR35","unstructured":"Lipiflow\u00ae Thermal Pulsation System. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf16\/K161357.pdf. Accessed on 23 December 2023"},{"issue":"2","key":"6587_CR36","doi-asserted-by":"publisher","first-page":"CD015448","DOI":"10.1002\/14651858.CD015448.pub2","volume":"2","author":"AD Pucker","year":"2024","unstructured":"Pucker AD, Yim TW, Rueff E, Ngo W, Tichenor AA, Conto JE (2024) LipiFlow for the treatment of dry eye disease. Cochrane Database Syst Rev 2(2):CD015448. https:\/\/doi.org\/10.1002\/14651858.CD015448.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"6587_CR37","unstructured":"FDA Approves Absorbable Punctual Plug. https:\/\/www.aao.org\/education\/headline\/fda-approves-absorbable-punctual-plug. Accessed on 23 December 2023"},{"key":"6587_CR38","unstructured":"Comfortear\u00ae Lacrisolve\u2122 Absorbable Punctum Plugs. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf14\/K140711.pdf. Accessed on 23 December 2023"},{"key":"6587_CR39","unstructured":"Surgidev Silicone Punctum Plug. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf\/K980844.pdf. Accessed on 23 December 2023"},{"issue":"6","key":"6587_CR40","doi-asserted-by":"publisher","first-page":"CD006775","DOI":"10.1002\/14651858.CD006775.pub3","volume":"6","author":"AM Ervin","year":"2017","unstructured":"Ervin AM, Law A, Pucker AD (2017) Punctal occlusion for Dry Eye Syndrome. Cochrane Database Syst Rev 6(6):CD006775. https:\/\/doi.org\/10.1002\/14651858.CD006775.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"6587_CR41","doi-asserted-by":"publisher","first-page":"704946","DOI":"10.1155\/2015\/704946","volume":"2015","author":"SP Phadatare","year":"2015","unstructured":"Phadatare SP, Momin M, Nighojkar P, Askarkar S, Singh KK (2015) Comprehensive Review on Dry Eye Disease: diagnosis, Medical Management, recent developments, and Future challenges. Adv Phamaceutics 2015:704946. https:\/\/doi.org\/10.1155\/2015\/704946","journal-title":"Adv Phamaceutics"},{"key":"6587_CR42","doi-asserted-by":"publisher","first-page":"9312340","DOI":"10.1155\/2016\/9312340","volume":"2016","author":"N Jehangir","year":"2016","unstructured":"Jehangir N, Bever G, Mahmood SM, Moshirfar M (2016) Comprehensive Review of the literature on existing Punctal Plugs for the management of Dry Eye Disease. J Ophthalmol 2016:9312340. https:\/\/doi.org\/10.1155\/2016\/9312340","journal-title":"J Ophthalmol"},{"issue":"1","key":"6587_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1089\/jop.2022.0119","volume":"39","author":"Y Eom","year":"2023","unstructured":"Eom Y, Yoon KC, Kim HK, Song JS, Hyon JY, Kim HM (2023) A Multicenter, Randomized, double-blind evaluation of the efficacy of TJO-087 Versus 0.05% cyclosporine A in moderate to severe Dry Eye. J Ocul Pharmacol Ther 39(1):27\u201335. https:\/\/doi.org\/10.1089\/jop.2022.0119","journal-title":"J Ocul Pharmacol Ther"},{"key":"6587_CR44","unstructured":"SCAI Therapeutics Press Release (2022). https:\/\/scaitrx.com\/news\/?mod=document&uid=7. Accessed on 23 December 2023"},{"key":"6587_CR45","unstructured":"Huons Press R (2022). https:\/\/www.cmocro.com\/news_detail\/Huons_Approves_Phase_3_Clinical_Trial_Plan_for_Complx_Eye_D\/758070\/index.html. Accessed on 23 December 2023"},{"issue":"1","key":"6587_CR46","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1089\/jop.2020.0104","volume":"37","author":"J Shin","year":"2021","unstructured":"Shin J, Rho CR, Hyon JY, Chung TY, Yoon KC, Joo CK (2021) A Randomized, Placebo-Controlled phase II clinical trial of 0.01% or 0.02% cyclosporin A with 3% trehalose in patients with Dry Eye Disease. J Ocul Pharmacol Ther 37(1):4\u201311. https:\/\/doi.org\/10.1089\/jop.2020.0104","journal-title":"J Ocul Pharmacol Ther"},{"key":"6587_CR47","unstructured":"IACTA Pharmaceuticals website. http:\/\/iactapharma.com\/products\/ic-265\/. Accessed on 23 December 2023"},{"key":"6587_CR48","unstructured":"Improved Dry Eye Drugs for 2022 and Beyond. https:\/\/www.aao.org\/eye-health\/tips-prevention\/new-dry-eye-treatments-ocular-surface-disease. Accessed on 23 December 2023"},{"key":"6587_CR49","unstructured":"NCT05992922. https:\/\/clinicaltrials.gov\/study\/NCT05992922. Accessed on 23 December 2023"},{"key":"6587_CR50","unstructured":"Okyo Pharma press release (2023). https:\/\/okyopharma.com\/okyo-pharma-announces-positive-safety-data-profile-for-the-ongoing-ok-101-phase-2-clinical-trial-to-treat-dry-eye-disease-ded\/. Accessed on 23 December 2023"},{"key":"6587_CR51","unstructured":"NCT05759208. https:\/\/clinicaltrials.gov\/study\/NCT05759208. Accessed on 27 January 2024"},{"issue":"9","key":"6587_CR52","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1089\/jop.2023.0056","volume":"39","author":"D Evans","year":"2023","unstructured":"Evans D, Kenyon K, Ousler G et al (2023) Efficacy and safety of the Melanocortin Pan-agonist PL9643 in a phase 2 study of patients with Dry Eye Disease. J Ocul Pharmacol Ther 39(9):600\u2013610. https:\/\/doi.org\/10.1089\/jop.2023.0056","journal-title":"J Ocul Pharmacol Ther"},{"key":"6587_CR53","unstructured":"NCT0520117. https:\/\/clinicaltrials.gov\/study\/NCT0520117. Accessed on 27 January 2024"},{"key":"6587_CR54","unstructured":"Palatin press release (2022). https:\/\/palatin.com\/press_releases\/palatin-reports-positive-interim-analysis-in-phase-3-pivotal-study-of-pl9643-in-patients-with-dry-eye-disease\/. Accessed on 23 December 2023"},{"key":"6587_CR55","unstructured":"Ousler GW, Jordan R, Spana C (2023) Effectiveness of PL9643 in Treating the Signs and Symptoms of Moderate to Severe Dry Eye Disease Including A Subpopulation of Hyper-Responders to CAE \u00ae Challenge: Results from 2 Independent Clinical Trials. Invest Ophthalmol Vis Sci. ; 64:3969. ARVO Annual Meeting Abstract 2023"},{"issue":"4","key":"6587_CR56","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/13543784.2018.1457647","volume":"27","author":"J Moreno-Monta\u00f1\u00e9s","year":"2018","unstructured":"Moreno-Monta\u00f1\u00e9s J, Bleau AM, Jimenez AI, Tivanisiran (2018) A novel siRNA for the treatment of Dry Eye Disease. Expert Opin Investig Drugs 27(4):421\u2013426. https:\/\/doi.org\/10.1080\/13543784.2018.1457647","journal-title":"Expert Opin Investig Drugs"},{"key":"6587_CR57","unstructured":"Sylentis press release (2023). https:\/\/sylentis.com\/sylentis-a-pharmamar-group-company-announces-the-fydes-study-to-evaluate-the-safety-of-tivanisiran-in-patients-with-dry-eye-disease-has-met-its-primary-endpoint\/. Accessed on 23 December 2023"},{"key":"6587_CR58","unstructured":"NCT04819269. https:\/\/clinicaltrials.gov\/study\/NCT04819269. Accessed on 27 January 2024"},{"key":"6587_CR59","unstructured":"NCT05310422. https:\/\/clinicaltrials.gov\/study\/NCT05310422. Accessed on 27 January 2024"},{"key":"6587_CR60","unstructured":"Hank Juo S-H, Liang C-L, Chen J-L (2022) lai W-Y. The Clinical Applications of Anti-microRNA-328 Therapy in Myopia Control and Dry Eye Disease. Invest Ophthalmol Vis Sci. ; 63:4213\u2013A0141. ARVO Annual Meeting Abstract 2022"},{"key":"6587_CR61","unstructured":"Sunhawk Vision website. http:\/\/www.sunhawkvision.com\/en\/. Accessed on 23 December 2023"},{"key":"6587_CR62","unstructured":"NCT05486728. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05486728. Accessed on 27 January 2024"},{"issue":"3","key":"6587_CR63","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1358\/dot.2023.59.3.3521858","volume":"59","author":"G Coco","year":"2023","unstructured":"Coco G, Piccotti G, Romano V et al (2023) Cenegermin for the treatment of Dry Eye Disease. Drugs Today (Barc) 59(3):113\u2013123. https:\/\/doi.org\/10.1358\/dot.2023.59.3.3521858","journal-title":"Drugs Today (Barc)"},{"key":"6587_CR64","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.2147\/OPTH.S185184","volume":"13","author":"H Sheha","year":"2019","unstructured":"Sheha H, Tighe S, Hashem O, Hayashida Y (2019) Update on Cenegermin Eye drops in the Treatment of Neurotrophic Keratitis. Clin Ophthalmol 13:1973\u20131980. https:\/\/doi.org\/10.2147\/OPTH.S185184","journal-title":"Clin Ophthalmol"},{"key":"6587_CR65","unstructured":"Dompe Press Release (2022). https:\/\/www.dompe.com\/media\/press-releases\/dompe-announces-first-patient-enrolled-in-phase-3-trial-of-cenegermin-in-patients-with-severe-sjogrens-related-dry-eye-disease. Accessed on 23 December 2023"},{"key":"6587_CR66","unstructured":"NCT05133180. https:\/\/clinicaltrials.gov\/study\/NCT05133180. Accessed on 27 January 2024"},{"key":"6587_CR67","unstructured":"NCT05136170. https:\/\/clinicaltrials.gov\/study\/NCT05136170. Accessed on 27 January 2024"},{"issue":"8","key":"6587_CR68","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1007\/s10792-022-02245-1","volume":"42","author":"Y Dong","year":"2022","unstructured":"Dong Y, Wang S, Cong L et al (2022) TNF-\u03b1 inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China. Int Ophthalmol 42(8):2459\u20132472. https:\/\/doi.org\/10.1007\/s10792-022-02245-1","journal-title":"Int Ophthalmol"},{"key":"6587_CR69","unstructured":"Harbour BioMed press release (2022). https:\/\/www.harbourbiomed.com\/news\/174.html. Accessed on 23 December 2023"},{"key":"6587_CR70","unstructured":"NCT04633213. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04633213. Accessed on 27 January 2024"},{"key":"6587_CR71","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.2147\/OPTH.S366836","volume":"16","author":"L Shettle","year":"2022","unstructured":"Shettle L, McLaurin E, Martel J, Seaman JW 3rd, Weissgerber G (2022) Topical Anti-TNF\u03b1 Agent Licaminlimab (OCS-02) relieves persistent ocular discomfort in severe Dry Eye Disease: a randomized phase II study. Clin Ophthalmol 16:2167\u20132177. https:\/\/doi.org\/10.2147\/OPTH.S366836","journal-title":"Clin Ophthalmol"},{"key":"6587_CR72","unstructured":"Oculis press release (2023). https:\/\/www.biospace.com\/article\/releases\/oculis-announces-first-patient-first-visit-in-phase-2b-relief-trial-of-topical-anti-tnf%CE%B1-licaminlimab-ocs-02-in-dry-eye-disease\/. Accessed on 23 December 2023"},{"key":"6587_CR73","unstructured":"NCT05896670. https:\/\/clinicaltrials.gov\/study\/NCT05896670. Accessed on 27 January 2024"},{"key":"6587_CR74","unstructured":"Mimetogen Pharmaceuticals Website. https:\/\/www.mimetogen.com\/clinical-development.html. Accessed on 23 December 2023"},{"key":"6587_CR75","unstructured":"NCT03925727. https:\/\/clinicaltrials.gov\/study\/NCT03925727. Accessed on 27 January 2024"},{"key":"6587_CR76","unstructured":"NCT05848128. https:\/\/clinicaltrials.gov\/study\/NCT05848128. Accessed on 27 January 2024"},{"key":"6587_CR77","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jtos.2022.08.003","volume":"26","author":"DL Wirta","year":"2022","unstructured":"Wirta DL, Senchyna M, Lewis AE et al (2022) A Randomized, Vehicle-controlled, phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of Dry Eye Disease (COMET-1). Ocul Surf 26:166\u2013173. https:\/\/doi.org\/10.1016\/j.jtos.2022.08.003","journal-title":"Ocul Surf"},{"key":"6587_CR78","unstructured":"Aerie Pharmaceuticals press release (2022) https:\/\/www.businesswire.com\/news\/home\/20220801005762\/en\/Aerie-Pharmaceuticals-Announces-First-Participant-Dosed-in-the-COMET-3-Study-of-AR-15512-for-the-Treatment-of-Dry-Eye-Disease. Accessed on 23 December 2023"},{"key":"6587_CR79","unstructured":"NCT05285644. https:\/\/clinicaltrials.gov\/study\/NCT05285644. Accessed on 27 January 2024"},{"key":"6587_CR80","unstructured":"NCT05360966. https:\/\/clinicaltrials.gov\/study\/NCT05360966. Accessed on 27 January 2024"},{"key":"6587_CR81","unstructured":"NCT05493111. https:\/\/clinicaltrials.gov\/study\/NCT05493111. Accessed on 27 January 2024"},{"key":"6587_CR82","unstructured":"Brim biotech press release. https:\/\/www.brimbiotech.com\/brm421\/. Accessed on 23 December 2023"},{"key":"6587_CR83","unstructured":"NCT04343287. https:\/\/clinicaltrials.gov\/study\/NCT04343287. Accessed on 27 January 2024"},{"key":"6587_CR84","unstructured":"NCT05695781. https:\/\/clinicaltrials.gov\/study\/NCT05695781. Accessed on 27 January 2024"},{"issue":"1","key":"6587_CR85","doi-asserted-by":"publisher","first-page":"31","DOI":"10.17925\/USOR.2023.17.1.31","volume":"17","author":"TS Swartz","year":"2023","unstructured":"Swartz TS, Powell W (2023) Reproxalap for the treatment of Dry Eye Disease. touchREVIEWS Ophthalmol 17(1):31\u201335. https:\/\/doi.org\/10.17925\/USOR.2023.17.1.31","journal-title":"touchREVIEWS Ophthalmol"},{"key":"6587_CR86","unstructured":"Aldeyra Therapeutics Inc website. https:\/\/www.aldeyra.com\/pipeline-disease-areas\/ocular-diseases\/dry-eye-disease\/. Accessed on 23 December 2023"},{"key":"6587_CR87","unstructured":"NCT03404115. https:\/\/clinicaltrials.gov\/study\/NCT03404115. Accessed on 27 January 2024"},{"key":"6587_CR88","unstructured":"NCT03445650. https:\/\/clinicaltrials.gov\/study\/NCT03445650. Accessed on 27 January 2024"},{"key":"6587_CR89","unstructured":"NCT03879863. https:\/\/clinicaltrials.gov\/study\/NCT03879863. Accessed on 27 January 2024"},{"key":"6587_CR90","unstructured":"NCT03916042. https:\/\/clinicaltrials.gov\/study\/NCT03916042. Accessed on 27 January 2024"},{"key":"6587_CR91","unstructured":"NCT04674358. https:\/\/clinicaltrials.gov\/study\/NCT04674358. Accessed on 27 January 2024"},{"key":"6587_CR92","unstructured":"NCT04735393. https:\/\/clinicaltrials.gov\/study\/NCT04735393. Accessed on 27 January 2024"},{"key":"6587_CR93","unstructured":"NCT04971031. https:\/\/clinicaltrials.gov\/study\/NCT04971031. Accessed on 27 January 2024"},{"key":"6587_CR94","unstructured":"NCT05062330. https:\/\/clinicaltrials.gov\/study\/NCT05062330. Accessed on 27 January 2024"},{"key":"6587_CR95","unstructured":"NCT05102409. https:\/\/clinicaltrials.gov\/study\/NCT05102409. Accessed on 27 January 2024"},{"key":"6587_CR96","unstructured":"NCT05424549. https:\/\/clinicaltrials.gov\/study\/NCT05424549. Accessed on 27 January 2024"},{"key":"6587_CR97","unstructured":"Hutton D FDA Issues Complete Response Letter to Aldeyra Therapeutics for Reproxalap NDA. https:\/\/www.optometrytimes.com\/view\/fda-issues-complete-response-letter-to-aldeyra-therapeutics-for-reproxalap-nda. Accessed on 23 December 2023"},{"key":"6587_CR98","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jtos.2023.07.002","volume":"29","author":"SL Watson","year":"2023","unstructured":"Watson SL, Jones LW, Stapleton F et al (2023) Efficacy and safety of AZR-MD-001 selenium Sulfide Ophthalmic ointment in adults with meibomian gland dysfunction: a Vehicle-controlled, Randomized Clinical Trial. Ocul Surf 29:537\u2013546. https:\/\/doi.org\/10.1016\/j.jtos.2023.07.002","journal-title":"Ocul Surf"},{"key":"6587_CR99","unstructured":"NCT03652051. https:\/\/clinicaltrials.gov\/study\/NCT03652051. Accessed on 27 January 2024"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06587-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-024-06587-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06587-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T09:03:04Z","timestamp":1725094984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-024-06587-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,31]]},"references-count":99,"alternative-id":["6587"],"URL":"https:\/\/doi.org\/10.1007\/s00417-024-06587-7","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,31]]},"assertion":[{"value":"13 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a review article and does not contain any studies with human participants and\/or animal studies performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors have no conflict of interest to declare for this review article. All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}